Host Species:	Rabbit
Concentration:	1 mg/ml (OD 1.35 / 280 nm)
Antigen:	4 HNE-BC
Purification:	Affinity purified
Buffer:	75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2, 30% glycerol
Specificity	Specifically binds to 4-HNE modified proteins. Dilution for immunoblot and ELISA range: 1,000 to 8,000. (A slight amount of precipitation may have occurred during storage due to the natural properties of these antibodies; please centrifuge before use.).
Use:	The antibody can be used for detection of of 4-HNE modification in plasma, lipoproteins, and other proteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

Importance

Modifications on lysine residues, with formation of carboxylmethyl-lysine (CML), malondialdehyde (MDA) and hexitol-lysine are advanced glycation end-products (AGE), and the coupling with reactive aldehyde compounds, such as 4-hydroxynonenal (4-HNE) may appear from lipid oxidation (Guichardant et al., 1998). These modifications feature the oxidative byproducts which react with NH2 groups and form Schiff-base adducts (Mark et al., 1996). LDL treated with HNE or oxidatively modified by Cu++ or by cultured endothelial cells give rise to Michael addition-type HNE adducts that are recognized by HNE-specific antibodies.

Guichardant M, Taibi-Tronche P, Fay LB, Lagarde M. Covalent modifications of aminophospholipids by 4-hydroxynonenal. Free Radic Biol Med. 1998 Dec;25(9):1049-56.

Mark S. Bolgar, Chao-Yuh Yang, and Simon J. Gaskell, First Direct Evidence for Lipid/Protein Conjugation in Oxidized Human Low Density Lipoprotein (LDL), JBC, 271: 27999-28001 (1996).

 

Citations

 

[A22][A23]	2013	Arashiki, Nobuto; Kimata, Naoki; Manno, Sumie; Mohandas, Narla; Takakuwa, Yuichi (2013): Membrane peroxidation and methemoglobin formation are both necessary for band 3 clustering: mechanistic insights into human erythrocyte senescence. In Biochemistry 52 (34), pp. 5760–5769. DOI: 10.1021/bi400405p.
[A22][A23]	2010	Yang, Xiaoling; Bosoi, Cristina R.; Jiang, Wenlei; Tremblay, Mélanie; Rose, Christopher F. (2010): Portacaval anastomosis-induced hyperammonemia does not lead to oxidative stress. In Metab Brain Dis 25 (1), pp. 11–15. DOI: 10.1007/s11011-010-9174-1.

academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种： 羊浓度： 1毫克/毫升（OD 1.35 / 280 nm）抗原： 人类载脂蛋白AII纯化： 亲和纯化缓冲： 75 mM磷酸钠，75 mM NaCl，0.5 mM EDTA，0.02％NaN3，pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围：1,000至80,000。用： 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII，免疫测定，免疫印迹，酶结合或生物素化。存储： -20°C长期保存，4°C短期保存。等分试样，以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途，不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，一项大型的欧洲前瞻性研究中的病例对照研究表明，血浆Apo AII浓度与冠心病事件密切相关（Birjmohun等，2007）。Birjmohun，RS，GM Dallinga-Thie，JA Kuivenhoven，ESg Stroes，JD Otvos，NJ Wareham，R.Luben，JJp Kastelein，K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116（2007）：2029-035。Brewer，HB，SE Lux，R.Ronan和KM John。“人ApoLp-Gln-II（apoA-II），一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5（1972）：1304-308。Warden，C.，C.Hedrick，J.Qiao，L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261（1993）：469-72。